- Home
- WYNN vs BBIO Comparison
WYNN vs BBIO Comparison
Compare WYNN & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WYNN
- BBIO
- Stock Information
- Founded
- WYNN 2002
- BBIO 2015
- Country
- WYNN United States
- BBIO United States
- Employees
- WYNN N/A
- BBIO N/A
- Industry
- WYNN Hotels/Resorts
- BBIO Biotechnology: Pharmaceutical Preparations
- Sector
- WYNN Consumer Discretionary
- BBIO Health Care
- Exchange
- WYNN Nasdaq
- BBIO Nasdaq
- Market Cap
- WYNN 12.2B
- BBIO 12.5B
- IPO Year
- WYNN 2002
- BBIO 2019
- Fundamental
- Price
- WYNN $126.04
- BBIO $70.06
- Analyst Decision
- WYNN Strong Buy
- BBIO Strong Buy
- Analyst Count
- WYNN 13
- BBIO 19
- Target Price
- WYNN $139.31
- BBIO $74.79
- AVG Volume (30 Days)
- WYNN 1.7M
- BBIO 2.7M
- Earning Date
- WYNN 11-06-2025
- BBIO 10-29-2025
- Dividend Yield
- WYNN 0.78%
- BBIO N/A
- EPS Growth
- WYNN N/A
- BBIO N/A
- EPS
- WYNN 4.59
- BBIO N/A
- Revenue
- WYNN $7,110,738,000.00
- BBIO $353,780,000.00
- Revenue This Year
- WYNN $0.86
- BBIO $123.32
- Revenue Next Year
- WYNN $4.30
- BBIO $73.46
- P/E Ratio
- WYNN $27.78
- BBIO N/A
- Revenue Growth
- WYNN N/A
- BBIO 62.46
- 52 Week Low
- WYNN $65.25
- BBIO $25.34
- 52 Week High
- WYNN $134.23
- BBIO $71.65
- Technical
- Relative Strength Index (RSI)
- WYNN 55.96
- BBIO 68.10
- Support Level
- WYNN $114.96
- BBIO $64.41
- Resistance Level
- WYNN $121.23
- BBIO $67.71
- Average True Range (ATR)
- WYNN 5.12
- BBIO 2.81
- MACD
- WYNN 0.09
- BBIO 0.23
- Stochastic Oscillator
- WYNN 58.36
- BBIO 86.49
About WYNN Wynn Resorts Limited Common stock
Wynn Resorts operates luxury casinos and resorts. The company was founded in 2002 by Steve Wynn, the former CEO. The company operates four megaresorts: Wynn Macau and Encore in Macao and Wynn Las Vegas and Encore in Las Vegas. Cotai Palace opened in August 2016 in Macao, and Encore Boston Harbor in Massachusetts opened June 2019. We expect the company to continue to build nongaming attractions in Macao over the next few years. We model Wynn's managed integrated resort in the United Arab Emirates to open in 2027. The company also operates Wynn Interactive, a digital sports betting and iGaming platform. The company received 76% and 24% of its 2019 prepandemic EBITDA from Macao and the US, respectively. In 2024, both the US and Macao were each 50% of total EBITDA.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.